New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Kozanoglu I., Yandim M. K., Cincin Z. B., Özdoğu H., Cakmakoglu B., Baran Y.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.139, no.2, pp.327-335, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 139 Issue: 2
  • Publication Date: 2013
  • Doi Number: 10.1007/s00432-012-1331-y
  • Journal Name: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.327-335
  • Keywords: Multiple myeloma, Propranolol, NF-kappa B pathway, Apoptosis, SIGNAL-TRANSDUCTION, MALT LYMPHOMA, BETA-BLOCKERS, CANCER, HEMANGIOMAS, MECHANISMS, FAMILY, GENE, INHIBITOR, CELLS
  • Istanbul University Affiliated: Yes

Abstract

Propranolol, a non-selective beta-adrenergic receptor blocker, has been used for the treatment of the patients with hypertension for more than 50 years. There are several in vitro and in vivo evidences that beta-adrenergic receptor antagonists inhibit proliferation and angiogenesis and also increase apoptosis in breast, skin, and colon cancers. The aim of this study was to investigate the cytotoxic and apoptotic effects of propranolol and the genes involved in propranolol-induced apoptosis in multiple myeloma cells.